The reputation of former pharmaceutical executive Martin Shkreli is making it a bit difficult to seat a jury in his federal fraud case.

Shkreli made headlines back in 2015 when he raised the price of a life-saving HIV drug by 5,000% as CEO of Turing Pharmaceuticals.

His current trial is not related to that price hike.

But a number of prospective jurors were let go yesterday when they said they could not ignore the increase.

During questioning, one of them described Shkreli as "the most hated man in America," while another called him "the face of corporate greed."

The 34-year-old is accused of stealing millions from a second pharmaceutical company to pay back losses from bad trades in a hedge fund he had on the side.

Jury selection in the case resumes today.